In this study, the natural Gal-3 inhibitor-modified MCP effectively regulated the progression of pancreatic cancer, which might be associated with the mechanism of gemcitabine action or regulatory signaling pathways. Here, LGALS3 is linked to familial pancreatic carcinoma.